Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
NRG Oncology
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
University of Arizona
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
University of Chicago
Case Comprehensive Cancer Center
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University of California, San Diego
European Organisation for Research and Treatment of Cancer - EORTC
Groupe Oncologie Radiotherapie Tete et Cou